Vaxil Bio (VXL) AI Stock Analysis

• Market Cap: C$356.14K
• Dividend Yield: N/A
• Average Volume (3M): 1.45K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.86
• Revenue Growth: N/A
• EPS Growth: 46.32%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 2,739,579
• 10 Day Avg. Volume: 1,125
• 30 Day Avg. Volume: 1,453
• PEG Ratio: 0.00
• Price to Book (P/B): 39.22
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -117.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: C$0.13 ▼(-3.85% Downside)

The score is primarily weighed down by weak financial performance (no revenue, ongoing losses and cash burn) despite some improvement in loss and burn trends, and by bearish technicals with price below key moving averages and negative MACD. Valuation provides limited support because the negative P/E reflects ongoing losses and there is no dividend yield data.

Positive Factors

Low Leverage / Positive Equity

Very low debt and positive equity materially reduce solvency risk and preserve strategic optionality. Over a 2–6 month horizon this balance-sheet strength supports continued R&D investment or partnership negotiations without immediate pressure to take restrictive financing, improving survival odds.

Narrowing Losses

A sustained narrowing of operating losses suggests improving cost discipline or R&D efficiency, which strengthens the pathway to eventual break-even. Over months this trend reduces future financing needs and increases the chance that incremental milestones convert to commercial or licensing opportunities.

Improved Cash Burn Trend

Meaningful reduction in cash burn extends the company’s runway and lowers immediate dilution risk. Structurally, a sustained improvement gives management more time to advance clinical programs, seek partnerships, or secure non-dilutive funding, improving execution flexibility mid-term.

Negative Factors

No Reported Revenue

Zero reported revenue indicates the business has not validated a commercial model; long-term viability depends on successful development or licensing. Over 2–6 months this maintains high execution and commercialization risk and keeps the company reliant on future clinical or partnership milestones.

Persistent Negative Cash Flow

Consistent negative operating and free cash flow means the company must access external capital to operate. Structurally, this creates dilution or debt risk, constrains strategic choices, and can delay or limit development activities absent new funding or a material change in business model.

Eroding Equity / Negative ROE

Declining shareholders' equity and negative ROE reflect accumulated losses and possible dilution, weakening long-term financial resilience. Over months this erodes investor confidence, reduces capital-raising flexibility, and can limit the company's ability to invest in growth or respond to setbacks without costly financing.

Vaxil Bio Business Overview & Revenue Model

Company Description

Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice. The company was founded in 2006 and is headquartered in Toronto, Canada.

How the Company Makes Money

Vaxil Bio generates revenue primarily through the development and commercialization of its immunotherapy products. The company's revenue streams include licensing agreements, strategic partnerships, and potential milestone payments associated with the advancement of its pipeline candidates. Additionally, Vaxil may seek to monetize its proprietary technology platform through collaborations with larger pharmaceutical companies, which can lead to upfront payments and royalties on sales of successfully commercialized products. However, as a biotechnology firm, Vaxil's revenue may be limited until its products reach later stages of development or receive regulatory approval, at which point sales and distribution could significantly contribute to its earnings.

Vaxil Bio Financial Statement Overview

Summary

Vaxil Bio faces significant challenges with no revenue generation and consistent financial losses impacting income statements. While the balance sheet remains stable with no debt, cash flow issues highlight operational sustainability concerns. The company must focus on revenue growth and operational efficiency to improve its financial health.

Income Statement

Vaxil Bio shows no revenue generation in the past periods, resulting in negative gross and net profit margins. The EBIT and EBITDA margins are also negative due to the absence of revenue, reflecting operational inefficiencies or high fixed costs. A lack of revenue growth highlights challenges in scaling operations or product commercialization.

Balance Sheet

The company's balance sheet shows stability with no debt and a positive equity position, indicating financial resilience and low leverage risk. However, the equity ratio has decreased over recent periods, suggesting a relative increase in liabilities. Nevertheless, the absence of debt reduces bankruptcy risk.

Cash Flow

Vaxil Bio's cash flow from operations is consistently negative, indicating challenges in sustaining operations without external financing. However, free cash flow has shown some improvement over the TTM, although it remains negative, suggesting continued operational cash burn without revenue offsets.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	-2.00K	-25.00K	-57.00K
EBITDA	-189.00K	-178.00K	-252.00K	-582.00K	-961.00K	-1.29M
Net Income	-99.00K	-178.00K	-254.00	-584.00K	-986.00K	-1.36M
Balance Sheet
Total Assets	697.00K	733.00K	976.00K	1.54M	2.29M	1.66M
Cash, Cash Equivalents and Short-Term Investments	347.00K	714.00K	938.00K	1.51M	2.24M	1.51M
Total Debt	0.00	0.00	0.00	0.00	0.00	9.00K
Total Liabilities	6.00K	17.00K	85.00K	405.00K	585.00K	857.00K
Stockholders Equity	691.00K	716.00K	891.00K	1.14M	1.70M	804.00K
Cash Flow
Free Cash Flow	-157.08K	-240.00K	-561.00K	-734.00K	-1.08M	-1.10M
Operating Cash Flow	-157.08K	-240.00K	-561.00K	-734.00K	-1.08M	-1.10M
Investing Cash Flow	0.00	-250.00K	0.00	0.00	0.00	0.00
Financing Cash Flow	0.00	0.00	0.00	0.00	1.81M	2.56M

Vaxil Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APS	51 Neutral	$5.72M	-0.20	―	―	―	90.81%
DTC	45 Neutral	C$35.02M	-9.04	―	―	―	72.92%
MDNA	44 Neutral	C$65.29M	-5.60	-91.21%	―	―	54.74%
BCT	44 Neutral	C$37.08M	-0.09	-409.25%	―	―	62.01%
VXL	43 Neutral	C$356.14K	-5.10	-10.82%	―	―	46.32%
BIOV	29 Underperform	C$7.14M	-1.10	―	―	―	25.09%

Vaxil Bio Corporate Events

Vaxil Bio Completes Private Placement and Updates Board

Vaxil Bio Ltd. has completed a non-brokered private placement, raising $140,000, which will be used to explore strategic options beyond the healthcare sector. The company has also announced changes to its board of directors, with the resignation of Mr. Ari Kellen and Mr. Shawn Langer and the appointment of Mr. Simon Igelman, a corporate transactional lawyer, as it seeks new strategic opportunities to benefit shareholders.

Vaxil Bio Revises Private Placement Terms to Raise $350,000

Vaxil Bio Ltd. has announced a revision to the terms of its previously announced offering, now planning a non-brokered private placement to raise up to $350,000 through the sale of 3,111,111 units. Each unit includes one common share and one share purchase warrant, with proceeds intended for general corporate purposes. The offering is subject to TSX Venture Exchange approval and is expected to close on December 4, 2025. This move is part of Vaxil’s strategy to support its operations and potentially explore new business avenues, reflecting its ongoing efforts to enhance shareholder value.

Vaxil Bio Announces $350,000 Private Placement to Support Corporate Growth

Vaxil Bio Ltd. has announced a non-brokered private placement to raise up to $350,000 through the issuance of 2,456,140 units, each comprising one common share and one share purchase warrant. The proceeds will be used for general corporate purposes, with the offering expected to close by mid-November 2025, pending TSX Venture Exchange approval. This move is part of Vaxil’s broader strategy to support its operations and explore new business opportunities, potentially impacting its market positioning and stakeholder interests.